Maze Therapeutics (MAZE) Cash & Equivalents (2024 - 2026)

Maze Therapeutics has reported Cash & Equivalents for 3 years, with the latest figure at $198.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 32.48% year-over-year to $198.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.8 million (down 32.48% YoY) and the FY2025 annual result came in at $189.2 million, down 3.84% from the prior year.
• Cash & Equivalents grew to $198.8 million in Q1 2026 per MAZE's latest filing, from $189.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $316.8 million in Q3 2025 and troughed at $30.0 million in Q1 2024.
• A 3-year average of $201.7 million and a median of $196.8 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 880.49% in 2025, then slumped 32.48% in 2026.
• Over 3 years, Cash & Equivalents stood at $196.8 million in 2024, then retreated by 3.84% to $189.2 million in 2025, then advanced by 5.03% to $198.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $198.8 million, $189.2 million, and $316.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.